Spots Global Cancer Trial Database for bruton's tyrosine kinase inhibitor
Every month we try and update this database with for bruton's tyrosine kinase inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | NCT02029443 | Chronic Lymphoc... Small Lymphocyt... Richter's Syndr... Prolymphocytic ... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01611090 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Bendamustine hy... Rituximab Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | NCT04402138 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | SCRI Development Innovations, LLC | |
| A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | NCT01599949 | Mantle Cell Lym... | Ibrutinib | 18 Years - | Janssen Research & Development, LLC | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT05190068 | B-Cell Non-Hodg... | HMPL-760 | 18 Years - | Hutchmed | |
| Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | NCT01646021 | Mantle Cell Lym... | Ibrutinib Temsirolimus | 18 Years - | Janssen Research & Development, LLC | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | NCT02514083 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | NCT04402138 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | SCRI Development Innovations, LLC | |
| Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | NCT05172700 | Leukemia, Lymph... Lymphoma, Lymph... Lymphoma, Mantl... Waldenstrom Mac... Ritcher's Trans... | Pirtobrutinib | 18 Years - | Eli Lilly and Company | |
| A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma | NCT03323151 | Mantle-Cell Lym... | Ixazomib Ixazomib Ibrutinib Ibrutinib | 18 Years - | PrECOG, LLC. | |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | NCT02029443 | Chronic Lymphoc... Small Lymphocyt... Richter's Syndr... Prolymphocytic ... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | NCT01855750 | Lymphoma | Ibrutinib Placebo Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone (or ... | 18 Years - | Janssen Research & Development, LLC | |
| Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | NCT06333262 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Obinutuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | NCT01855750 | Lymphoma | Ibrutinib Placebo Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone (or ... | 18 Years - | Janssen Research & Development, LLC | |
| Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | NCT06333262 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Obinutuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | NCT01599949 | Mantle Cell Lym... | Ibrutinib | 18 Years - | Janssen Research & Development, LLC | |
| Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL | NCT02419560 | Lymphoma, Mantl... Recurrent Lymph... | ABT-199 and Ibr... | 18 Years - | University of Virginia | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | NCT01855750 | Lymphoma | Ibrutinib Placebo Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone (or ... | 18 Years - | Janssen Research & Development, LLC | |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | NCT04402138 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | SCRI Development Innovations, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
